Evidence map›Paper›PMID 40134122›Full record

ArticleJournal of medicinal chemistry2025

Deconstruction of Dual-Site Tankyrase Inhibitors Provides Insights into Binding Energetics and Suggests Critical Hotspots for Ligand Optimization.

Sven T Sowa, Murat Kücükdisli, Yelena Mostinski, David A Schaller, Carolina S Vinagreiro, Davide Cirillo, Chiara Bosetti, Shoshy Alam Brinch, Kirsten van Laar, Anita Wegert and 6 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sven T SowaFaculty for Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Aapistie 7, 90220 Oulu, Finland.
Murat KücükdisliMedicinal Chemistry, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin Buch, Robert-Roessle-Str. 10, 13125 Berlin, Germany.
Yelena MostinskiMedicinal Chemistry, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin Buch, Robert-Roessle-Str. 10, 13125 Berlin, Germany.
David A SchallerIn Silico Toxicology and Structural Bioinformatics, Institute of Physiology, Charité Universitätsmedizin Berlin, Virchowweg 6, 10117 Berlin, Germany.ORCID 0000-0002-1881-4518
Carolina S VinagreiroMedicinal Chemistry, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin Buch, Robert-Roessle-Str. 10, 13125 Berlin, Germany.
Davide CirilloMedicinal Chemistry, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin Buch, Robert-Roessle-Str. 10, 13125 Berlin, Germany.ORCID 0000-0001-5133-0702
Chiara BosettiFaculty for Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Aapistie 7, 90220 Oulu, Finland.
Shoshy Alam BrinchOslo University Hospital, P.O. Box 4950, Nydalen, 0424 Oslo, Norway.
Kirsten van LaarSymeres Netherlands B.V., Kerkenbos 1013, 6546 BB Nijmegen, The Netherlands.
Anita WegertSymeres Netherlands B.V., Kerkenbos 1013, 6546 BB Nijmegen, The Netherlands.
Ruben G G LeendersSymeres Netherlands B.V., Kerkenbos 1013, 6546 BB Nijmegen, The Netherlands.ORCID 0000-0001-6140-5405
Stefan KraussOslo University Hospital, P.O. Box 4950, Nydalen, 0424 Oslo, Norway.
Jo WaalerOslo University Hospital, P.O. Box 4950, Nydalen, 0424 Oslo, Norway.
Andrea VolkamerIn Silico Toxicology and Structural Bioinformatics, Institute of Physiology, Charité Universitätsmedizin Berlin, Virchowweg 6, 10117 Berlin, Germany.ORCID 0000-0002-3760-580X
Lari LehtiöFaculty for Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Aapistie 7, 90220 Oulu, Finland.ORCID 0000-0001-7250-832X
Marc NazaréMedicinal Chemistry, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin Buch, Robert-Roessle-Str. 10, 13125 Berlin, Germany.ORCID 0000-0002-1602-2330

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Designing inhibitors is a complex task that requires a deep understanding of protein-ligand interactions and their dynamics. Ligands often interact with multiple binding subsites, with noncovalent interactions affecting binding affinity. Conformational changes and plasticity of both, the ligand and the protein influence binding energetics. We investigated the tankyrase ADP-ribosyltransferase as a promising drug target regulating many cellular pathways. Despite the existence of diverse tankyrase inhibitors, their binding energetics and contributions of flexible cryptic subpockets to binding affinity remain elusive. To examine these aspects, we deconstructed inhibitors to key fragments, dissected their energetic contribution to the affinity, and determined their binding mode by X-ray crystallography. Varying ligand efficiencies of the deconstructed, pocket-binding fragments revealed the cryptic nature of subpockets. These insights enabled us to redesign inhibitors with novel linkers, the observed key area for optimization, increasing the potency in enzymatic and cell-based assays by 7.5-fold and 6.2-fold compared to the parent ligand.

Indexed as

Enzyme InhibitorsTankyrasesBinding SitesCrystallography, X-RayHumansLigandsModels, MolecularProtein BindingStructure-Activity RelationshipEnzyme InhibitorsLigandsTankyrases

Identifiers

PMID40134122
PMCPMC11997991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.